11:09 AM EDT, 05/29/2024 (MT Newswires) -- MannKind ( MNKD ) said Wednesday it has agreed to in-license Pulmatrix's ( PULM ) iSPERSE technology for certain indications in exchange for an out-license to its Cricket inhaler for inhaled delivery of dihydroergotamine for migraine treatment.
The two companies also agreed that Pulmatrix ( PULM ) will transfer its Bedford, Massachusetts R&D facility to MannKind ( MNKD ), along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory in non-cash transaction.
The deal is expected to close in July. Financial terms were not disclosed.
MannKind ( MNKD ) shares were more than 3% lower in recent trading, while Pulmatrix ( PULM ) was more than 4% higher.
Price: 4.47, Change: -0.17, Percent Change: -3.56